Determinants of immune reconstitution inflammatory syndrome in HIV type 1-infected patients with tuberculosis after initiation of antiretroviral therapy

Clinical Infectious Diseases

Volumn 39, Issue 11, 2004, Pages 1709-1712

  Breton, Guillaume ^a   Duval, Xavier ^a   Estellat, Candice ^a   Poaletti, Xavier ^a   Bonnet, Daniel ^a   Mvondo, David Mvondo ^a   Longuet, Pascale ^a   Leport, Catherine ^a   Vildé, Jean Louis ^a  

^a BICHAT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CD8 ANTIGEN; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STEROID; TUBERCULOSTATIC AGENT; VIRUS RNA;

ADULT; ARTHRITIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DYSPNEA; FEMALE; FEVER; FOLLOW UP; FRANCE; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNOPATHOLOGY; INFLAMMATION; LUNG INFILTRATE; LYMPHADENOPATHY; LYMPHOCYTE COUNT; MALE; MYCOBACTERIUM TUBERCULOSIS; OSTEOMYELITIS; PAROTITIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SKIN DISEASE; SPLEEN ABSCESS; SPLEEN RUPTURE; SPUTUM CULTURE; THROMBOEMBOLISM; TUBERCULOSIS; URETER DISEASE; URINE CULTURE;

ADULT; ANTI-RETROVIRAL AGENTS; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SYNDROME; TUBERCULOSIS;

EID: 9644301108     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/425742     Document Type: Article

References (16)

1. Narita M, Ashkin D, Hollender ES, Pitchenik AE. Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. Am J Respir Crit Care Med 1998; 158:157-61.
2. Fishman JE, Saraf-Lavi E, Narita M, Hollender ES, Ramsinghani R, Ashkin D. Pulmonary tuberculosis in AIDS patients: transient chest radiographic worsening after initiation of antiretroviral therapy. AJR Am J Roentgenol 2000; 174:43-9.
3. Wendel KA, Alwood KS, Gachuhi R, Chaisson RE, Bishai WR, Sterling TR. Paradoxical worsening of tuberculosis in HIV-infected persons. Chest 2001; 120:193-7.
4. Navas E, Martin-Davila P, Moreno L, et al. Paradoxical reactions of tuberculosis in patients with the acquired immunodeficiency syndrome who are treated with highly active antiretroviral therapy. Arch Intern Med 2002; 162:97-9.
5. Olalla J, Pulido F, Rubio R, et al. Paradoxical responses in a cohort of HIV-1-infected patients with mycobacterial disease. Int J Tuberc Lung Dis 2002; 6:71-5.
6. DeSimone JA, Pomerantz RJ, Babinchak TJ. Inflammatory reactions in HIV-1 infected persons after initiation of highly active antiretroviral therapy. Ann Intern Med 2000; 133:447-54.
7. Shelburne SA 3rd, Hamill RJ, Rodriguez-Barradas MC, et al. Immune reconstitution inflammatory syndrome: emergence of an unique syndrome during highly active antiretroviral therapy. Medicine 2002; 81: 213-27.
8. Cheng VC, Yam WC, Woo PC, et al. Risk factors for development of paradoxical response during antituberculosis therapy in HIV-negative patients. Eur J Clin Microbiol Infect Dis 2003; 22:597-602.
9. Jones BE, Young SM, Antoniskis D, Davidson PT, Kremer F, Barnes PF. Relationship of the manifestations of tuberculosis to CD4 cell counts in patients with human immunodeficiency virus infection. Am Rev Respir Dis 1993; 148:1292-7.
10. Burns FM, Fakoya AO, Copas AJ, French PD. Africans in London continue to present with advanced HIV disease in the era of highly active antiretroviral therapy. AIDS 2001; 15:2453-5.
11. Dean GL, Edwards SG, Ives NJ, et al. Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy. AIDS 2002; 16:75-83.
12. + T cell homeostasis and function in advanced HIV disease. Science 1997; 277:112-6.
13. Valdez H, Smith KY, Landay A, et al. Response to immunization with recall and neoantigens after prolonged administration of an HIV-1 protease inhibitor-containing regimen. ACTG 375 team. AIDS Clinical Trials Group. AIDS 2000; 14:11-21.
14. Stone SF, Price P, Brochier J, French MA. Plasma bioavailable interleukin-6 is elevated in human immunodeficiency virus-infected patients who experience herpesvirus-associated immune restoration disease after start of highly active antiretroviral therapy. J Infect Dis 2001; 184:1073-7.
15. Karavellas MP, Plummer DJ, Macdonald JC, et al. Incidence of immune recovery vitritis in cytomegalovirus retinitis patients following institution of successful HAART. J Infect Dis 1999; 179:697-700.
16. Foundraine NA, Hovenkamp E, Notermans DW, et al. Immunopathology as a result of highly active antiretroviral therapy in HIV-1-infected patients. AIDS 1999; 13:177-84.